Role of granulocyte colony stimulating factor in the treatment of cirrhosis of liver: a systematic review.

ABSTRACT:

Objective

We performed a systematic review to analyze the benefits of and risk factors associated with granulocyte colony stimulating factor (GCSF) in patients with liver cirrhosis.

Methods

PubMed, Scopus, and Embase were searched for randomized controlled trials and case-control studies that compared the use of GCSF with another treatment or control group. The Jadad and Newcastle-Ottawa scales were used to assess the risk of bias in the included studies. The primary outcome studied was mortality; and the secondary outcomes were the disease severity score, liver transplantation criteria, complications, CD34⁺ cell count, adverse events, and health-related quality of life (HRQOL). PROSPERO registration number CRD42023416014.

Results

The initial search yielded

SUBMITTER: Rajpurohit S 

PROVIDER: S-EPMC10637184 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature